Abstracts tagged "ANCA"

Abstract Number: 1863 • 2014 ACR/ARHP Annual Meeting
CCX168, an Orally Administered C5aR Inhibitor for Treatment of Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Pirow Bekker¹, David Jayne², Annette Bruchfeld³, Matthias Schaier⁴, Kazimierz Ciechanowski⁵, Lorraine Harper⁶, Michel Jadoul⁷, Mårten Segelmark⁸, Daina Selga⁹, Istvan Szombati¹⁰, Michael Venning¹¹, Christian Hugo¹², Paul L. van Daele¹³, Ondrej Viklicky¹⁴, Antonia Potarca¹⁵ and Thomas J. Schall¹⁵, ¹Medical & Clinical Affairs, Chemocentryx, Inc., Mountain View, CA, ²Vasculitis and Lupus Clinic, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, ³Karolinska Institute, Stockholm, Sweden, ⁴University of Heidelberg, Heidelberg, Germany, ⁵Pomeranian Medical University, Szczecin, Poland, ⁶Nephrology, University of Birmingham, Birmingham, United Kingdom, ⁷Cliniques Saint-Luc, Brussels, Belgium, ⁸Nephrology, Linkobing University, Linkoping University, Linkoping, Sweden, ⁹Lund University, Lund, Sweden, ¹⁰Budaclinic, Budapest, Hungary, ¹¹Manchester University, Manchester, United Kingdom, ¹²Dresden University, Dresden, Germany, ¹³Erasmus Medical Center, Immunology, Rotterdam, Netherlands, ¹⁴Instit of Clin and Exp Med, Prague, Czech Republic, ¹⁵ChemoCentryx, Inc., Mountain View, CA
Background/Purpose: CCX168 is a potent, specific C5aR inhibitor in clinical development for ANCA-associated vasculitis. The initial focus of this randomized, double-blind, placebo-controlled clinical trial was…
Abstract Number: 1862 • 2014 ACR/ARHP Annual Meeting
The Association of Low-Density Granulocytes with Disease Activity and Response to Treatment in ANCA-Associated Vasculitis
Peter C. Grayson¹, Carmelo Carmona-Rivera¹, Lijing Xu², Noha Lim², Adam Asare², Deborah J. Phippard², Mariana J. Kaplan³, Peter A. Merkel⁴ and Paul A. Monach⁵, ¹NIAMS Systemic Autoimmunity Branch, National Institutes of Health, Bethesda, MD, ²Immune Tolerance Network, Bethesda, MD, ³Systemic Autoimmunity Branch, Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Section of Rheumatology, Vasculitis Center, Boston University School of Medicine, Boston, MA
Background/Purpose: To discover new pathways involved in the pathophysiology of ANCA-associated vasculitis (AAV) and identify potential clinical biomarkers through use of whole-genome gene expression profiling.…
Abstract Number: 1777 • 2014 ACR/ARHP Annual Meeting
Staphylococcus Aureus Nasal Carriage and Relapses, Bvas, ANCA-Positivity and Cotrimoxazole Use in ANCA-Associated Vasculitis
Boun Kim Tan¹, Yoann Crabol¹, Jason Tasse^2,3, Frederic Laurent^2,3, Xavier Puechal^4,5, Christine Vinter⁶ and Loïc Guillevin^1,5, ¹Internal Medicine, Hôpital Cochin, University Paris V Descartes, Paris, France, ²Laboratoire de Bactériologie de l'hôpital de la Croix-Rousse, National Reference Centre for Staphylococci, Lyon, France, ³INSERM U1111, CNRS UMR5308, International Centre for Research in Infectious Diseases, Lyon, France, ⁴Internal Medicine, Hôpital Cochin, Paris, France, ⁵French Vasculitis Study Group (FVSG), Paris, France, ⁶Internal Medecine, Hôpital Cochin, Paris, France
Background/Purpose Staphylococcus aureus (SA) nasal carriage has been reported to be more frequent and associated with persistent ANCA-positivity and relapse in patients with granulomatosis with…
Abstract Number: 1776 • 2014 ACR/ARHP Annual Meeting
Factors Predictive of ANCA-Associated Vasculitis Relapse in Patients Given Rituximab-Maintenance Therapy
Benjamin Terrier¹, Christian Pagnoux², Guillaume Geri³, Alexandre Karras⁴, Chahéra Khouatra⁵, Olivier Aumaitre⁶, Pascal Cohen⁷, Francois Maurier⁸, Olivier Decaux⁹, Hélène Desmurs-Clavel¹⁰, Pierre Gobert¹¹, Thomas Quemeneur¹², Claire Blanchard-Delaunay¹³, Pascal Godmer¹⁴, Xavier Puéchal⁷, Luc Mouthon⁷ and Loïc Guillevin for the French Vasculitis Study Group⁷, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ²Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ³Intensive Care Unit, Cochin Hospital, Paris, France, ⁴Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, ⁵CHU Louis Pradel, Lyon, Lyon, France, ⁶Internal Medicine, CHU, Clermont-Ferrand, France, ⁷National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ⁸HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, ⁹Department of Internal Medicine, Rennes University Hospital, Rennes, France, ¹⁰University of Lyon, LYON, France, ¹¹Nephrology, Centre Hospitalier d'Avignon, Avignon, France, ¹²Internal Medicine, CH, Valenciennes, France, ¹³Internal Medicine, Hôpital de Niort, Niort, France, ¹⁴Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France
Background/Purpose Rituximab (RTX) was shown to be as effective as cyclophosphamide to induce remission in patients with ANCA-associated vasculitis (AAV). The prospective MAINRITSAN trial compared…
Abstract Number: 1775 • 2014 ACR/ARHP Annual Meeting
Predicting Relapse in Patients with Granulomatosis with Polyangiitis – the Potential Use of Monitoring in Vitro ANCA Production
Judith Land¹, Wayel H. Abdulahad¹, Coen A. Stegeman², Peter Heeringa³ and Abraham Rutgers¹, ¹Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ²Nephrology, University Medical Center Groningen, Groningen, Netherlands, ³Pathology and Medical Biology, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose Patients with granulomatosis with polyangiitis (GPA) suffer from frequent disease relapses, with up to 50% of patients relapsing within 5 years. Several risk factors…
Abstract Number: 1773 • 2014 ACR/ARHP Annual Meeting
Otolaryngologic Lesions Are Not Rare and Closely Related with Pachymeningitis and Cranial Neuropathy in MPO-ANCA Associated Vasculitis
Takahiro Nunokawa¹, Naoto Yokogawa², Kota Shimada¹ and Shoji Sugii², ¹Department of Rheumatic diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, ²Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan
Background/Purpose: Recently several case reports of serous otitis media (SOM), hypertrophic pachymeningitis (HP) and cranial neuropathy (CN) have been reported in connection with MPO-ANCA associated…
Abstract Number: 733 • 2013 ACR/ARHP Annual Meeting
Plasma Levels Of Fibrin/Fibrinogen Degradation Products Might Be a Useful Indicator Of Disease Activity, Classification and Nephritis Complications In Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Kuninobu Wakabayashi, Nao Oguro, Yoko Miura, Sho Ishii, Shinya Seki, Masayu Umemura, Takahiro Tokunaga, Hiroyuki Tsukamoto, Sakiko Isojima, Hidekazu Furuya, Ryo Yanai, Kumiko Otsuka, Ryo Takahashi, Takeo Isozaki, Nobuyuki Yajima, Yusuke Miwa and Tsuyoshi Kasama, Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan
Background/Purpose: It is important to determine the biomarkers for assessing disease activity of patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Plasma levels of fibrin/fibrinogen…
Abstract Number: 734 • 2013 ACR/ARHP Annual Meeting
The Significance Of Anti-Myeloperoxidase and Anti-Proteinase 3 Antibodies In The Absence Of Anti-Neutrophil Cytoplasmic Antibody Immunofluorescence Positivity
Deepak A. Rao¹, Joseph F. Merola¹, William R. O'Brien¹, Kevin Wei¹, Samuel U. Takvorian², Paul F. Dellaripa³ and Peter H. Schur¹, ¹Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Internal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Identification of serum anti-neutrophil cytoplasmic antibodies (ANCA) for the detection of ANCA-associated vasculitis (AAV) is often performed by screening with indirect immunofluorescence (IF), followed…
Abstract Number: 736 • 2013 ACR/ARHP Annual Meeting
Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Associated With Systemic Sclerosis In Japan: A Review Of The Literature
Natsumi Nagao¹, Yuri Sadanaga¹, Satoko Tashiro¹, Rie Suematsu¹, Syuichi Koarada¹, Akihide Ohta² and Yoshifumi Tada¹, ¹Rheumatology, Saga University, Saga, Japan, ²Nursing, Saga University, Saga, Japan
Background/Purpose: Cases of Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) during the course of systemic sclerosis (SSc) have recently been reported. Japanese cases of AAV associated…
Abstract Number: 149 • 2013 ACR/ARHP Annual Meeting
Comparative Proteomic Analysis Of Neutrophils From Patients With Microscopic Polyangiitis and Granulomatosis With Polyangiitis
Teisuke Uchida¹, Kohei Nagai², Toshiyuki Sato³, Nobuko Iizuka³, Mitsumi Arito³, Yukiko Takakuwa⁴, Hiromasa Nakano⁴, Seido Ooka⁴, Manae Kurokawa³, Naoya Suematsu³, Kazuki Okamoto³, Shoichi Ozaki⁵ and Tomohiro Kato³, ¹Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, kawasaki, Japan, ²Department of Genetic Engineering, Faculty of Biology-Oriented Science and Technology, Kinki University, Wakayama, Japan, ³Clinical Proteomics and Molecular Medicine, St. Marianna University Graduate School of Medicine, Kawasaki, Japan, ⁴Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁵Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Both microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) belong to ANCA-associated vasculitis (AAV), in which neutrophils are thought to be involved in their…
Abstract Number: 738 • 2013 ACR/ARHP Annual Meeting
Pulmonary Fibrosis In ANCA-Associated Vasculitis
Cloé Comarmond¹, Bruno Crestani², Abdellatif Tazi³, Baptiste Hervier⁴, Sylvain Adam-Marchand⁵, Hilario Nunes⁶, Fleur Cohen-Aubart⁷, Marie Wislez⁸, Jacques Cadranel⁸, Bruno Housset⁹, Célia Lloret-Linares¹⁰, Pascal Sève¹¹, Christian Pagnoux¹², Sébastien Abad¹³, Juliette Camuset¹⁴, Boris Bienvenu¹⁵, Michael Duruisseaux¹⁶, Eric Hachulla¹⁷, Jean-Benoît Arlet¹⁸, Mohamed Hamidou¹⁹, Alfred Mahr²⁰, Anne-Laure Brun²¹, Philippe Grenier²¹, Patrice Cacoub²² and David Saadoun²³, ¹Internal Medicine and Clinical Imunology, Referal Center for Autoimmune diseases, Internal Medicine and Clinical Imunology, Hôpital Pitié Salpétrière, Paris, France, ²Pneumology A, Hôpital Bichat, Paris, France, ³Hôpital Saint-Louis, Paris, France, ⁴Internal Medicine & Clinical Immunology Dpt, Pitié-Salpêtrière Hospital, APHP, Paris, France, ⁵Pneumology, Centre Hospitalier Universitaire de Tours, Tours, France, ⁶Department of Pneumology, Avicenne Hospital (AP-HP), Bobigny, France, ⁷Internal Medicine Dpt 2, Pitié-Salpêtrière Hospital, APHP, Paris, France, ⁸Pneumology, Hôpital Tenon, Paris, France, ⁹Pneumology, Centre Hospitalier Intercommunal de Créteil, Créteil, France, ¹⁰Médecine Interne A, Hôpital Lariboisière, Paris, France, ¹¹Internal medicine, CHU Lyon, Lyon, France, ¹²Rheumatology, Mount Sinai Hospital, Toronto, Canada, Toronto, ON, Canada, ¹³Internal Medicine, Avicenne Hospital, Bobigny, France, ¹⁴Pneumology, Centre Hospitalier Victor Dupouy, Argenteuil, France, ¹⁵Division of Internal Medicine, Centre Hospitalier Régional Universitaire de Caen, Côte de Nacre, Caen, France, Caen, France, ¹⁶Pneumology, CHU de Grenoble, Grenoble, France, ¹⁷Internal Medicine, Lille CEDEX, France, ¹⁸Internal Medicine, HEGP, Paris, France, ¹⁹Internal Medicine Department, Nantes University Hospital, Nantes, France, ²⁰Department of Internal Medicine, Hospital Saint-Louis, Paris, France, ²¹Radiology, Hôpital Pitié-Salpêtrière, Paris, France, ²²Médecine Interne 2, Hopital Pitié-Salpétrière, Paris, France, ²³Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France
Background/Purpose: The association of pulmonary fibrosis (PF) with anti neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV), especially microscopic polyangiitis (MPA), is rare but related to poor…
Abstract Number: 741 • 2013 ACR/ARHP Annual Meeting
Granulomatosis With Polyangiitis Central Nervous System Involvement: Presentation and Management
Gonzalo De Luna^1,2, Benjamin Terrier³, Pierre Kaminsky⁴, Francois Maurier⁵, Roser Solans⁶, Raphaèle Seror⁷, Xavier Puéchal⁸, Luc Mouthon⁹ and Loic Guillevin¹⁰, ¹Medecine Interne, Cochin University Hospital, Paris, France, ²Internal Medicine, Hospital Ramon y Cajal, Madrid, Spain, ³Internal Medicine, Cochin University Hospital, Paris, France, ⁴Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Orphan disease unit, Nancy, F-54000, France;, Nancy, France, ⁵HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, ⁶Autoimmune Systemic Diseases Unit, Department of Internal Medicine, Hospital Vall d'Hebron, Autonomous University of Barcelona, Barcelona, Spain, ⁷Rheumatology, Bicetre university hospital, LE Kremlin-Bicetre, France, ⁸National Referral Center for Rare Systemic Auto-immune Diseases, Hôpital Cochin, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, ⁹Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ¹⁰Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose: Granulomatosis with polyangiitis (GPA), a small-sized–vessel vasculitis, commonly involves ear, nose & throat (ENT), lungs and kidneys, and, more rarely, the central nervous system…
Abstract Number: 2782 • 2013 ACR/ARHP Annual Meeting
Retreatment With Rituximab In The Rituximab In ANCA-Associated Vasculitis (RAVE) Trial
Eli Miloslavsky¹, Ulrich Specks², Peter A Merkel³, Philip Seo⁴, Robert F. Spiera⁵, Carol A. Langford⁶, Gary S. Hoffman⁷, Cees G.M. Kallenberg⁸, E. William St Clair⁹, Nadia Tchao¹⁰, Linna Ding¹¹, David Ikle¹², Brett Jepson¹², Paul Brunetta¹³ and John H. Stone¹⁴, ¹Division of Rheumatology, Massachusetts General Hopsital, Boston, MA, ²Mayo Clinic, Rochester, MN, ³Division of Rheumatology, University of Pennsylvania and VA Medical Center, Philadelphia, PA, ⁴Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ⁵Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁷Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁸Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ⁹Medicine, Duke Unversity Medical Center, Durham, NC, ¹⁰Immune Tolerance Network, Bethesda, MD, ¹¹NIAID, Bethesda, MD, ¹²Rho, Chapel Hill, NC, ¹³Biotherapeutics, Genentech, So San Francisco, CA, ¹⁴Rheumatology, Massachusetts General Hospital, Boston, MA
Background/Purpose: Retrospective studies have demonstrated that repeat rituximab treatment may be effective in re-inducing remission in relapsing ANCA-associated vasculitis. We analyzed data from the Rituximab…
Abstract Number: 743 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Rituximab For Otolaryngologic (ENT) Manifestations Of Granulomatosis With Polyangiitis (GPA, Wegener’s granulomatosis)
Lindsay Lally¹, Robert Lebovics², Wei-Ti Huang³ and Robert F. Spiera¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Otolaryngology, St. Luke's-Roosevelt Hospital Center, New York, NY, ³Biostatistics, Hospital for Special Surgery, New York, NY
Background/Purpose: ENT involvement is the most prevalent manifestation of GPA. Rituximab (RTX) is a proven effective remission induction therapy for severe GPA with vasculitic manifestations. …
Abstract Number: 2784 • 2013 ACR/ARHP Annual Meeting
Mononeuritis Multiplex Predicts The Need For Immunosuppressive Or Immunomodulatory Drugs For Eosinophilic Granulomatosis With Polyangiitis, Polyarteritis Nodosa and Microscopic Polyangiitis Patients Without Poor-Prognosis Factors
Maxime Samson¹, Xavier Puéchal², Hervé Devilliers³, Camillo Ribi⁴, Pascal Cohen⁵, Boris Bienvenu⁶, Christian Pagnoux⁷, Luc Mouthon², Loic Guillevin⁸ and French Vasculitis Study Group (FVSG)², ¹Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France; Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ²Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ³Dijon University Hospital, Department of internal medicine and systemic diseases, Dijon, France, ⁴Immunology and Allergology, Internal Medicine, University Hospitals of Geneva, Geneva, Switzerland, Geneva, Switzerland, ⁵National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ⁶Division of Internal Medicine, Centre Hospitalier Régional Universitaire de Caen, Côte de Nacre, Caen, France, Caen, France, ⁷Rheumatology, Mount Sinai Hospital, Toronto, Canada, Toronto, ON, Canada, ⁸Department of Internal Medicine,, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose: Patients with eosinophilic granulomatosis with polyangiitis (EGPA), polyarteritis nodosa (PAN) or microscopic polyangiitis (MPA) without poor-prognosis factors, as defined by their 1996 Five-Factor Scores…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].